Zyrorab IT 20mg/150mg Capsule SR is a combination medication containing Rabeprazole 20mg and Itopride 150mg, formulated for sustained release to provide effective management of gastrointestinal disorders. Rabeprazole, a proton pump inhibitor, acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion and promoting ulcer healing. Itopride, a prokinetic agent, enhances gastrointestinal motility by antagonizing dopamine D2 receptors and inhibiting acetylcholinesterase activity, facilitating gastric emptying and alleviating symptoms such as bloating, nausea, and discomfort associated with delayed gastric emptying. The combined action of Rabeprazole and Itopride addresses both acid-related mucosal damage and impaired motility, making Zyrorab IT suitable for conditions like gastroesophageal reflux disease (GERD), functional dyspepsia, and other acid-peptic disorders with associated motility disturbances. The sustained-release formulation ensures prolonged therapeutic effects, improving patient compliance by reducing dosing frequency. Zyrorab IT should be used under medical supervision, with dosage adjustments based on clinical response and tolerability. Contraindications include hypersensitivity to any component and caution is advised in patients with hepatic impairment. Common adverse effects may include headache, diarrhea, and abdominal discomfort.